United-States-Insulin-Pump-Market-Insights-Opportunity-Analysis-Growth-Potential-and-Forecast-2017-2022-grandresearchstore
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> <strong>Insights</strong>, <strong>Opportunity</strong>,<br />
<strong>Analysis</strong>, <strong>Growth</strong> <strong>Potential</strong> & <strong>Forecast</strong> <strong>2017</strong> – <strong>2022</strong><br />
Published On : March <strong>2017</strong><br />
Category : Life Sciences<br />
Pages : 145 pages<br />
Contact : International : (+1) 646 781 7170 help@gr<strong>and</strong>researchstore.com<br />
Report Description:<br />
<strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> is likely to reach USD 4 Billion by the year end of <strong>2022</strong>.<br />
<strong>Market</strong> growth can be attributed to factors such as increasing number of diabetic patients,<br />
growing awareness towards diabetes, improved glucose control <strong>and</strong> flexible, lifestylecompatible<br />
treatment options <strong>and</strong> technological advancement in insulin pump devices.<br />
However, high cost of the insulin pumps is hampering the growth of this market.<br />
The research report titled “<strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> <strong>Insights</strong>, <strong>Opportunity</strong>,<br />
<strong>Analysis</strong>, <strong>Growth</strong> <strong>Potential</strong> & <strong>Forecast</strong> <strong>2017</strong> – <strong>2022</strong>” examines the market, competitive<br />
l<strong>and</strong>scape <strong>and</strong> trends of the <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong>. The report provides an indepth<br />
analysis of the type 1, type 2 <strong>and</strong> newly diagnosed type 1 diabetes <strong>and</strong> overall<br />
diabetes population. It provides essential insights into insulin pump users with more focused<br />
on type 1 <strong>and</strong> type 2 diabetes insulin pump users. <strong>Market</strong> outlook in value terms for the<br />
forecasted period for <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> has been detailed in the report. It also covers<br />
reimbursement pattern <strong>and</strong> offers a clear view of the regulatory l<strong>and</strong>scape. Additionally, the<br />
report includes assessment of clinical trials <strong>and</strong> preferred insulin pump br<strong>and</strong> by the<br />
patients. Key trends in terms of collaborations, partnerships <strong>and</strong> licensing agreements are<br />
analysed with details. The report also explores detailed description of growth drivers <strong>and</strong><br />
inhibitors of the <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong>.
The report concludes with the profiles of major players in the <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> such as<br />
Insulet Corporation, Medtronic, Roche, Animas Corporation <strong>and</strong> T<strong>and</strong>em Diabetes Care. The<br />
major market players are evaluated on various parameters such as company overview,<br />
product outlook <strong>and</strong> sales analysis of the <strong>Insulin</strong> <strong>Pump</strong> <strong>and</strong> Diabetes <strong>Market</strong> from 2011 to<br />
<strong>2022</strong>.<br />
Key Topics Covered in the Report<br />
• <strong>United</strong> <strong>States</strong> Diabetes Population (2011 – <strong>2022</strong>)<br />
• <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> Users <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> (2011 – <strong>2022</strong>)<br />
• <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> Preferred Br<strong>and</strong> – By Product<br />
• <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong>: Reimbursement & Regulation System<br />
• <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Major Deal Types<br />
• <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> Clinical Trail Insight by Phase, Company & Country<br />
• Key Companies <strong>Analysis</strong><br />
• Key Drivers <strong>and</strong> Inhibitors of the <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong><br />
Key Companies Covered in the Report are as follows:<br />
• Insulet Corporation<br />
• Medtronic<br />
• Roche<br />
• Animas Corporation<br />
• T<strong>and</strong>em Diabetes Care<br />
Table of contents:<br />
Table of Contents<br />
1. Executive Summary<br />
2. <strong>United</strong> <strong>States</strong> Diabetes Population (2011 – <strong>2022</strong>): An <strong>Analysis</strong><br />
2.1 Overall Diabetes Population<br />
2.1.1 Type 1 Diabetes<br />
2.1.2 Type 2 Diabetes<br />
2.1.3 Newly Diagnosed Type 1 Diabetes<br />
3. <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> <strong>Analysis</strong> (2011– <strong>2022</strong>)<br />
3.1 <strong>Insulin</strong> <strong>Pump</strong> Users<br />
3.1.1 Type 1 Diabetes <strong>Insulin</strong> <strong>Pump</strong> Users
3.1.2 Type 2 Diabetes <strong>Insulin</strong> <strong>Pump</strong> Users<br />
3.2 <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong><br />
4. Key Drivers <strong>and</strong> Inhibitors of the <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong><br />
4.1 <strong>Market</strong> Drivers<br />
4.2 Inhibitors<br />
5. <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> Preferred Br<strong>and</strong> – By Product<br />
5.1 Pediatric<br />
5.2 Adult<br />
6. <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong>: Reimbursement & Regulation System<br />
6.1 Reimbursement System<br />
6.2 Regulation System<br />
7. <strong>United</strong> <strong>States</strong> <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Major Deal Types<br />
7.1 <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Collaboration Deals<br />
7.2 <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Licensing Agreement<br />
7.3 <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Exclusive Agreement<br />
7.4 <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> – Partnerships Deals<br />
8. <strong>Insulin</strong> <strong>Pump</strong> <strong>Market</strong> Clinical Trail Insight by Phase, Company & Country<br />
8.1 Year 2016<br />
8.2 Year 2015<br />
8.3 Year 2014<br />
8.4 Year 2013<br />
8.5 Year 2012<br />
9. Key Companies <strong>Analysis</strong><br />
9.1 Medtronic<br />
9.1.1 Business Overview<br />
9.1.2 <strong>Insulin</strong> <strong>Pump</strong> – Product Details<br />
9.1.3 Medtronic – <strong>United</strong> <strong>States</strong> Diabetes Sales <strong>Analysis</strong> & <strong>Forecast</strong> (2013 – <strong>2022</strong>)<br />
9.1.4 <strong>Insulin</strong> <strong>Pump</strong> – Latest Development & Trends<br />
9.2 T<strong>and</strong>em Diabetes Care<br />
9.2.1 Business Overview<br />
9.2.2 <strong>Insulin</strong> <strong>Pump</strong> – Product Details<br />
9.2.3 T<strong>and</strong>em Diabetes Care – <strong>Insulin</strong> <strong>Pump</strong> Sales <strong>Analysis</strong> & <strong>Forecast</strong> (2013 – <strong>2022</strong>)<br />
9.2.4 <strong>Insulin</strong> <strong>Pump</strong> – Latest Development & Trends<br />
9.3 Insulet Corporation<br />
9.3.1 Business Overview<br />
9.3.2 <strong>Insulin</strong> <strong>Pump</strong> – Product Details<br />
9.3.3 Insulet Corporation – <strong>Insulin</strong> <strong>Pump</strong> Sales <strong>Analysis</strong> & <strong>Forecast</strong> (2011 – <strong>2022</strong>)<br />
9.3.4 <strong>Insulin</strong> <strong>Pump</strong> – Latest Development & Trends
9.4 Animas Corporation (Johnson & Johnson)<br />
9.4.1 Business Overview<br />
9.4.2 <strong>Insulin</strong> <strong>Pump</strong> – Product Details<br />
9.4.3 Johnson & Johnson – <strong>United</strong> <strong>States</strong> Diabetes Sales <strong>Analysis</strong> & <strong>Forecast</strong> (2013 – <strong>2022</strong>)<br />
9.4.4 <strong>Insulin</strong> <strong>Pump</strong> – Latest Development & Trends<br />
9.5 Roche<br />
9.5.1 Business Overview<br />
9.5.2 <strong>Insulin</strong> <strong>Pump</strong> – Product Details<br />
9.5.3 Roche – North America Diabetes Sales <strong>Analysis</strong> & <strong>Forecast</strong> (2011 – <strong>2022</strong>)<br />
9.5.4 <strong>Insulin</strong> <strong>Pump</strong> – Latest Development & Trends<br />
Get full report details at:<br />
https://www.gr<strong>and</strong>researchstore.com/life-sciences/<strong>United</strong>-<strong>States</strong>-<strong>Insulin</strong>-<strong>Pump</strong><br />
-<strong>Market</strong>-<strong>Insights</strong>-<strong>Opportunity</strong>-<strong>Analysis</strong>-<strong>Growth</strong>-<strong>Potential</strong>-<strong>and</strong>-<br />
<strong>Forecast</strong>-<strong>2017</strong>-<strong>2022</strong>
Change language